Abstract:202 Background: Treatment options that are durably effective for patients with metastatic (m) castration-resistant prostate cancer (CRPC) remain limited despite available therapies, highlighting a continued unmet need for novel drug development. hK2 is overexpressed in prostate cancer (PC) and has little to no expression in non-prostate tissues. Here, we use a series of preclinical experiments to evaluate hK2 as a therapeutic target in PC. Methods: hK2 expression was assessed by immunohistochemistry (IHC) in non-metastatic (nm) castration sensitive PC (CSPC; n = 100), mCSPC (n = 98), and mCRPC (n = 45) samples obtained from tumor banks and warm autopsy tumor microarrays. Multiplex immunofluorescence (IF) was used to assess hK2 expression at different mCRPC tumor sites. hK2 cell surface expression in a human prostate cancer cell model (VCaP) and fresh mCRPC patient tumor samples was assessed by flow cytometry. hK2-targeting antibody internalization over time was visualized by confocal IF microscopy in VCaP cells. VCaP xenograft models in immune-compromised NSG mice were used to evaluate anti-tumor activity, defined as change in percent of tumor growth inhibition (ΔTGI), following treatment with 3 unique hK2-targeting experimental agents (Table). Whole-body planar and SPECT/CT imaging were used to assess hK2-targeting antibody tumor uptake in patients with mCRPC. Results: IHC confirmed robust hK2 expression across different PC stages with homogenous expression in nm/mCSPC and increased heterogeneity in mCRPC. Mean percent tumor staining of hK2 in mCRPC samples was 67.6% (bone), 65.7% (lymph nodes), and 33.5% (liver) by multiplex IF. Correlation of hK2 expression across mCRPC bony lesions (r = 0.74, p < 1.6e -06 ) was observed, suggesting intrapatient and interlesion homogeneity. Confocal microscopy demonstrated hK2 cell surface expression in VCaP cells, with rapid antibody internalization within 3 hours. Flow cytometry confirmed hK2 cell surface expression in both VCaP cells and mCRPC samples. Robust antitumor activity was observed following treatment with each hK2-targeting agent in the xenograft mouse model (Table). Whole-body and SPECT/CT scans confirmed accumulation of the hK2-targeting antibody to PC tumors in patients with mCRPC. Conclusions: hK2 expression was homogenous in nm/mCSPC, with increased heterogeneity in mCRPC. Antitumor activity was observed across hK2-targeting agents. These data demonstrate that therapeutic strategies targeting hK2 hold promise in PC treatment and support further investigation of these agents in clinical studies. [Table: see text]

Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 2 with a Highly Selective Inhibitor for the Treatment of Prostate Cancer

Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 2 (DYRK2) with a Highly Selective Inhibitor for the Treatment of Prostate Cancer

Discovery of Potent DYRK2 Inhibitors with High Selectivity, Great Solubility, and Excellent Safety Properties for the Treatment of Prostate Cancer

Discovery of Potent, Selective, and Orally Bioavailable DYRK2 Inhibitors for the Treatment of Prostate Cancer

Synergistic Anticancer Effect by Targeting CDK2 and EGFR-ERK Signaling.

Targeting ADAR1 with a Novel Small-Molecule for the Treatment of Prostate Cancer

Choosing Kinase Inhibitors for Androgen Deprivation Therapy-Resistant Prostate Cancer

Discovery of a small-molecule NDR1 agonist for prostate cancer therapy

Selective inhibition reveals the regulatory function of DYRK2 in protein synthesis and calcium entry

Targeting signaling pathways in prostate cancer: mechanisms and clinical trials

Human Kallikrein 2 (KLK2) Promotes Prostate Cancer Cell Growth Via Function As a Modulator to Promote the ARA70-enhanced Androgen Receptor Transactivation.

Discovery of Pyridine Tetrahydroisoquinoline Thiohydantoin Derivatives with Low Blood-Brain Barrier Penetration As the Androgen Receptor Antagonists.

Design, synthesis and biological evaluation of dual inhibitors targeting AR/AR-Vs and PARP1 in castration resistant prostate cancer therapy

Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors.

Preclinical characterization of human Kallikrein 2 (hK2) as a novel target for the treatment of prostate cancer.

Casein kinase 2 inhibition attenuates androgen receptor function and cell proliferation in prostate cancer cells.

Y08197 is a Novel and Selective CBP/EP300 Bromodomain Inhibitor for the Treatment of Prostate Cancer

Co‐targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating AKT signaling with induction of senescence and apoptosis

Suppression of Androgen Receptor Transactivation by Pyk2 Via Interaction and Phosphorylation of the ARA55 Coregulator*

Discovery and biological evaluation of novel CARM1/HDAC2 dual-targeting inhibitors with anti-prostate cancer agents

Co-targeting Hexokinase 2-Mediated Warburg Effect and ULK1-dependent Autophagy Suppresses Tumor Growth of PTEN- and TP53- Deficiency-Driven Castration-Resistant Prostate Cancer